Top Markets
#1 Orochi Network Orochi Network +75.87%
#2 Bitway Bitway +26.98%
#3 Audiera Audiera +26.10%
#4 RSK Infrastructure Framework RSK Infrastructure Framework +18.52%
#5 Pharos Pharos +15.97%
#6 SOON SOON +15.22%
#7 DeXe DeXe +14.77%
#8 Taiko Taiko +14.38%
#9 Cap Cap +13.75%
#10 Cheems Token Cheems Token +13.12%
Coin of the day
Orochi Network Orochi Network
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Rangering i aksjer #72
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Aksjekurs
$50.93
Markedsverdi
$226.32B
Endring (1 dag)
2.54%
Endring (1 år)
-26.19%
Land
DK
Handel Novo Nordisk A/S (NVO)

Kategori

Healthcare
Inntekter for Novo Nordisk A/S (NVO)
Inntekter i Mar 2026 TTM: $24.72B
Ifølge Novo Nordisk A/S sine nyeste økonomiske rapporter er selskapets nåværende resultat $24.72B. I 2024 hadde selskapet et resultat på $17.75B, en økning sammenlignet med resultatet i 2023, som var $15.50B. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Novo Nordisk A/S fra 2000 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $24.72B 25.36%
2025 $19.72B 11.11%
2024 $17.75B 14.50%
2023 $15.50B 55.92%
2022 $9.94B 10.02%
2021 $9.03B 3.59%
2020 $8.72B 19.69%
2019 $7.29B -0.35%
2018 $7.31B -6.79%
2017 $7.84B 15.64%
2016 $6.78B 7.06%
2015 $6.34B 14.26%
2014 $5.55B -7.59%
2013 $6.00B 22.00%
2012 $4.92B 28.80%
2011 $3.82B 16.43%
2010 $3.28B 21.42%
2009 $2.70B 13.54%
2008 $2.38B 10.14%
2007 $2.16B 33.54%
2006 $1.62B 24.30%
2005 $1.30B -5.19%
2004 $1.37B 6.85%
2003 $1.28B 44.62%
2002 $888.11M 23.73%
2001 $717.79M 18.82%
2000 $604.10M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.17B -79.10%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.16B -79.14%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -91.35%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.48B -94.01%
NL
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
ALNY.US
$586.40M -97.63%
US